In this interview, Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, DE) and Prof Marianne Brodmann (Medical University of Graz, AT) explain what the Spur System is and the mode of action for Spur RST followed by a drug-coated balloon (DCB).

They share their insights from the DEEPER LIMUS and DEEPER OUS studies, discussing the outcomes, patient benefits and identifying which patients are likely to benefit the most.

The information presented and the device featured is CE Mark approved for use in the EU. The Spur is indicated for treatment of de novo or restenotic infrapopliteal lesions, with reference vessel diameters ranging from 2.5 – 4.5mm, prior to treatment with a commercially available drug coated balloon.